Novartis Ag (NVS) Receivables - Net (2017 - 2025)
Novartis Ag's Receivables - Net history spans 9 years, with the latest figure at $8.9 billion for Q4 2025.
- For Q4 2025, Receivables - Net rose 20.4% year-over-year to $8.9 billion; the TTM value through Dec 2025 reached $8.9 billion, up 20.4%, while the annual FY2025 figure was $8.9 billion, 20.4% up from the prior year.
- Receivables - Net for Q4 2025 was $8.9 billion at Novartis Ag, up from $7.4 billion in the prior quarter.
- Across five years, Receivables - Net topped out at $8.9 billion in Q4 2025 and bottomed at $7.1 billion in Q4 2023.
- The 5-year median for Receivables - Net is $8.0 billion (2021), against an average of $7.9 billion.
- The largest annual shift saw Receivables - Net decreased 11.89% in 2023 before it increased 20.4% in 2025.
- A 5-year view of Receivables - Net shows it stood at $8.0 billion in 2021, then increased by 0.76% to $8.1 billion in 2022, then dropped by 11.89% to $7.1 billion in 2023, then rose by 4.45% to $7.4 billion in 2024, then rose by 20.4% to $8.9 billion in 2025.
- Per Business Quant, the three most recent readings for NVS's Receivables - Net are $8.9 billion (Q4 2025), $7.4 billion (Q4 2024), and $7.1 billion (Q4 2023).